title: Effect of beta 2-agonists on histamine-induced airway microvascular leakage in ozone-exposed guinea pigs.
abstract: beta 2-adrenergic agonists exhibit antipermeability effects in the airways. However, it is not known whether beta 2-agonists have this beneficial effect in airway mucosa that is already inflamed. We evaluated the effects of two inhaled beta 2-agonists, salbutamol and formoterol, on the histamine-induced bronchoconstriction and plasma extravasation in the airways of guinea pigs with or without ozone exposure. Total pulmonary resistance (RL) was measured before and after histamine inhalation in anesthetized animals that were pretreated with inhaled salbutamol, formoterol, or saline. Plasma extravasation in the airways was measured using Evans blue dye. In the control animals not exposed to ozone, salbutamol and formoterol each significantly reduced both the histamine-induced bronchoconstriction and the plasma extravasation in the trachea and main bronchi. In the ozone-exposed animals, the increase in RL after histamine was greater than that in control animals. Salbutamol and formoterol each significantly reduced histamine-induced bronchoconstriction, even in the ozone-exposed animals. Salbutamol did not affect the histamine-induced plasma extravasation, whereas formoterol reduced the plasma extravasation in the main bronchi, but not in the trachea, of the animals exposed to ozone. These results suggest that the anti-inflammatory properties of formoterol in inflamed airways may contribute to the beneficial effects in the treatment of airway inflammation.
authors.affiliation: Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Inoue
authors.forename: H
authors.initials: H
authors.lastname: Aizawa
authors.forename: K
authors.initials: K
authors.lastname: Matsumoto
authors.forename: M
authors.initials: M
authors.lastname: Shigyo
authors.forename: S
authors.initials: S
authors.lastname: Takata
authors.forename: M
authors.initials: M
authors.lastname: Hara
authors.forename: N
authors.initials: N
authors.lastname: Hara
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000403:Airway Resistance / Q000187:drug effects; D000420:Albuterol / Q000627:therapeutic use*; D000818:Animals; D015824:Blood-Air Barrier / Q000187:drug effects*; D016535:Bronchial Hyperreactivity / Q000139:chemically induced* / Q000188:drug therapy*; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004983:Ethanolamines / Q000627:therapeutic use*; D015633:Extravascular Lung Water / Q000187:drug effects*; D000068759:Formoterol Fumarate; D006168:Guinea Pigs; D006632:Histamine / Q000009:adverse effects*; D008297:Male; D010083:Oxidants, Photochemical / Q000633:toxicity*; D010126:Ozone / Q000633:toxicity*
chemical_list: D000318:Adrenergic beta-Agonists; D004983:Ethanolamines; D010083:Oxidants, Photochemical; D010126:Ozone; D006632:Histamine; D000420:Albuterol; D000068759:Formoterol Fumarate